Moderna Inc ASCO Call Transcript
Good evening, everyone, and welcome to Moderna's ASCO 2023 event. We're so happy to welcome you here. Today, we have both Stephen Hoge, President of the company; as well as Kyle Holen, Head of Therapeutics -- Oncology and Therapeutics, here to review some of the data that we presented at ASCO. As a reminder, this is an IR event, and we will be making forward-looking statements. Please refer to the Slide #2 on the webcast relating to the risks associated with everything we're about to say today. And with that, I will hand it over to Stephen.
Great. Thank you, Lavina. So I'll make some brief remarks -- that's going to be a problem -- and then turn it over to Kyle to walk through the data. So first of all, thank you for everybody who's come here to hear this. We're really looking forward to completing the picture of our first primary analysis in this mRNA-4157, previously called PCV, now called individualized neoantigen therapy, Phase II trial. This trial, as you
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |